Thank you for joining!
Thank you to our Sponsors!
2
Agenda – all times are listed in Eastern Time Zone 5:30 - 5:35 PM – Welcome and Announcements w/ Dr. Brian G.M. Durie 5:35 – 6:00 PM – Myeloma 101 Brian G.M. Durie, MD, International Myeloma Foundation
6:00 – 6:15 PM – Q&A 6:15 – 6:40 PM – Taking the Reins of Your Myeloma Care Mary Steinbach, DNP, APRN, Hunstman Cancer Institute, University of Utah, IMF Nurse Leadership Board Member
6:40 – 6:55 PM – Q&A 6:55 – 7:05 PM - BREAK
Agenda – all times are listed in Pacific Time Zone 7:05 – 7:30 PM – Frontline Therapy Rafat Abonour, MD, Indiana University School of Medicine
7:30 – 7:45 PM – Q&A 7:45 – 8:15 PM – Relapse & Immune Therapies Ajai Chari, MD, University of California San Francisco
8:15 – 8:30 PM – Q&A 8:30 PM – Closing Remarks
IMF Patient and Family Webinar
Myeloma 101 November 2, 2023
Brian G.M. Durie, MD International Myeloma Foundation Studio City, CA
0
What is Myeloma? Multiple myeloma is a cancer of the bone marrow. • The malignant cell is a MYELOMA CELL • Symptoms are CRAB features • Tracked using Monoclonal (M) protein • Very treatable with current therapies 2
CRAB Clinical Features
3
Monoclonal Protein Analysis
4
Immunofixation
5
Skeletal Survey
6
MRI Scan
7
PET/CT Scan
8
Investigations for Diagnosis
9
Tests to do at Baseline for Prognosis
10
Myeloma is treatable ► Over 90% of patients respond to current therapies ►Average first remission is 4 years or more ►In 2023, average survival is at least 7-10 years ►Some patients live over 15-20 years ►New therapies are constantly improving the outlook 11
Myeloma Expert Consultation Helps! ►Good to do early! ►Virtual consults can be explored. ►Sets path for future ►Guides local doctor SEE: Questions to ask your doctor
https://www.myeloma.org/resource-library/tip-card-ask-your-doctor-these-important-questions
12
Careful testing required for diagnosis and monitoring ►Bone marrow indicates % myeloma ►X-rays/ scans show where lesions* are located X-ray image of myeloma lesions in arm
Myeloma cells as seen in a bone marrow aspirate
See further discussion: “What is a lesion?” https://www.myeloma.org/bone-disease
13
More Test Details ►Bone marrow FiSH shows chromosome results ►MRI and PET/CT show more lesions than x-rays FISH
PET
MRI F
F
D D D
FiSH – Fluorescent in Situ Hybridization See: https://www.myeloma.org/videos/imaging-studies-or-scans-should-myeloma-patients-undergo
F
D D
D
Colored spots show translocations: t(11;14)
F
PET F = Focal D = Diffuse
14
Managing Myeloma: The Components Transplant Eligible Patients
Transplant Ineligible patients
Transplant
Maintenance
Initial Therapy Consolidation/ Maintenance/ Continued therapy Supportive Care
Reference: https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.25791
15
Treatment Combinations NEWER
VD Rev/Dex CyBorD VTD VRD KRD IRD Dara + triplet
SCT VD/VRD
Front line treatment
Induction
OLD
Thal/Dex VAD DEX
Consolidation
SCT
Lenalidomide Bortezomib Ixazomib Daratumumab Pomalidomide
Maintenance
Thalidomide Bortezomib Lenalidomide Carfilzomib Ixazomib Pomalidomide Daratumumab Isatuximab Elotuzumab Panobinostat Bendamustine Selinexor Belantamab Mafodotin Melphalan Flufenamide (Melflufen)
Relapsed
Post consolidation
Rescue
Nothing Prednisone Thalidomide
Few options
16
Immunotherapy
17
Immunotherapy Timeline
18
S0777 Trial: VRd vs Rd Eight 21-day Cycles of VRd
Randomization N = 525 Newly diagnosed MM
• •
Stratification: ISS (I, II, III) Intent to transplant @ progression (yes/no)
Bortezomib 1.3/mg2 IV Days 1, 4, 8, and 11 Lenalidomide 25 mg/day PO Days 1-14 Dexamethasone 20 mg/day PO Days 1, 2, 4, 5, 8, 9, 11, 12
Six 28-day Cycles of Rd Lenalidomide 25 mg/day PO Days 1-21 Dexamethasone 40 mg/day PO Days 1, 8, 15, 22
6 month of triplet followed by doublet Reference: Durie BGM, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017 Feb 4;389(10068):519-527. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546834
118 9
S0777 Trial: VRd vs Rd
41 months
Durie et al. Blood Cancer Journal (2020) 10:53 https://www.nature.com/articles/s41408-020-0311-8
OS 80% = 4 years 55% = 7 years
219
What to Expect with Treatment First “biochemical” relapse
100% Myeloma protein level
Deep first response 50%
MRD Undetected
Second response Later relapse from MRD undetected
Possible MRD undetected
5 years
10 years 21
Treatment Options
►“Triple therapy”: 3 drugs recommended • Most common = VRd* [Rd for older/frail] (Velcade®/ Revlimid®/ dexamethasone) ►ASCT (Autologous Stem Cell Transplant) ► Can be considered to achieve better response (after 3-6 months of VRd) Plus Zometa®/ Aredia or denosumab for bone lesions * Other options include VCd (CyBorD); KRd; Dara + Rd; Vd 22
Treatment Strategies in 2023 ►
Triplets or quadruplets in frontline
►
Maintenance based upon risk
►
Decisive early relapse treatment (triplets if feasible)
►
Earlier use of new immune therapies 23
IMF Publications
Publications available at no-charge: https://www.myeloma.org/publications
24
IMF Website – http://www.myeloma.org http://www.myeloma.org
25
Q&A
with panel
33
Taking The Reins of Your Multiple Myeloma Care Mary Steinbach, DNP, APRN Huntsman Cancer Institute University of Utah
STABLE OF TREATMENT FINDING YOUR GAIT GOING THE DISTANCE
Today’s Topics
STABLE OF TREATMENT Myeloma and treatment options, side effects, symptom management, & supportive care
35
FINDING YOUR GAIT Know your care team, telehealth & meeting prep, & shared decision making
GOING THE DISTANCE Healthful living, infection prevention, renal and bone health
Stable of Treatment Treatment options, side effects, symptom management, and supportive care
36
STABLE OF TREATMENT FINDING YOUR GAIT GOING THE DISTANCE
STABLE OF TREATMENT FINDING YOUR GAIT GOING THE DISTANCE
Treatment Goals
Myeloma Therapies
Rapid and effective disease control Durable disease control Improved overall survival Minimize side effects Allow good quality of life
Supportive Treatment
Prevent disease- and treatment-related side effects Optimize symptom management Allow good quality of life
Discuss goals and priorities with your healthcare team. 37
Stable of Treatment Options -Mibs
-MAbs
-Mides
Steroids
FRONTLINE
Velcade® (bortezomib)
Darzalex® (daratumumab)
Thalomid® (thalidomide) Revlimid® (lenalidomide)
Dexamethasone Prednisone Prednisolone SoluMedrol
MAINTENANCE
Velcade® (bortezomib) Ninlaro® (ixazomib)
Darzalex® (daratumumab) - ECOG clinical trial
Revlimid® (lenalidomide)
RELAPSE
Kyprolis® (carfilzomib) Ninlaro® (ixazomib)
Darzalex® (daratumumab) Empliciti® (elotuzumab) Sarclissa® (Isatuximab)
Thalomid® (thalidomide) Revlimid® (lenalidomide) Pomalyst® (pomalidomide)
Dexamethasone Prednisone Prednisolone SoluMedrol
Alkylators
ImmunoTherapy
STABLE OF TREATMENT FINDING YOUR GAIT GOING THECellular Others DISTANCE Therapies
Melphalan Cyclophosphamide
Melphalan Cyclophosphamide Bendamustine
ASCT
Tecvayli™ Teclistamab Talvey™ Talquetamab
Xpovio® (Selinexor) Doxil (liposomal doxorubicin)
ASCT CAR-T cell therapy Ide-Cel Cilta-Cel
Venclexta® (venetoclax)
Other CAR-T
• Bispecific PENDING FDA APPROVAL
NOTED SIDE EFFECTS
Antibodies ‒ Cevostamab • Antibody Drug Conjugates* ‒ Belantamab mafodotin
• CelMods ‒ Iberdomide ‒ CC-92480
Neuropathy Carfilzomib: Cardiac
Infusion reaction
DVT/PE
See steroid slide
Myelosuppression
CRS and Myelosuppression, GI neurotoxicity; infection risk; Selinexor: Low sodium Blenrep: Keratopathy
38 ASCT = autologous stem cell transplant; CAR-T cell therapy; CRS = cytokine release syndrome; DVT = deep vein thrombosis; PE = pulmonary embolism *Withdrawn from FDA but still available in certain situations IMF Nurse Leadership Board ONS Symposia 2022; NCCN Guidelines. Multiple Myeloma. V3.2022. Accessed January 13, 2023.
Infection risk CAR-T: CRS and neurotoxicity
CAR T: A New Treatment Approach
39
STABLE OF TREATMENT FINDING YOUR GAIT GOING THE DISTANCE
CAR T: Tips
• Ask for a referral to CAR T-cell therapy center before relapse – – – –
Insurance preauthorization required (weeks, maybe longer) Must have sufficient blood count and organ function to be eligible Must be able to wait or have bridging therapy Manufacturing CAR T-cell therapy is limited: center-specific “wait list” processes
• In patient for ≈ 1 week when CAR T administered • Patients need a caregiver and must stay within proximity of CAR T-cell
therapy center for ≈ 1 month
CAR T-CELLS
Viral vector
Patient own T cell Cytotoxi c cytokine s
sc Fv MM cell
• No driving for 8 weeks • One and done…BUT will need ongoing monitoring; some patients need
transfusion support 40
• CRS, neurotoxicity, or infection are possible side effects
STABLE OF TREATMENT FINDING YOUR GAIT GOING THE DISTANCE
MM cell death
BCMA
STABLE OF TREATMENT FINDING YOUR GAIT GOING THE DISTANCE BISPECIFIC ANTIBODIES
Horse of Another Color: Bispecific Antibodies also Target BCMA
• Different bispecific antibodies have differences in efficacy, side effects
About 7 in 10 patients responded CRS is common Some had skin/nail disorders • Tecvayli™ (teclistamab) is the first but more expected • Off-the-shelf treatment; no waiting for engineering cells • Route of administration and dosing schedule will vary depending on product • CRS, neurotoxicity, or infection are possible side effects – – –
Cytotoxic cytokines MM cell
T cell
CD3
Bispecific antibody
MM cell death
41
BCMA = B-cell maturation antigen; CAR = chimeric antigen receptor; MM = multiple myeloma; scFV = single chain fragment variable. Shah N, et al. Leukemia. 2020;34(4):985-1005. Yu B, et al. J Hematol Oncol. 2020;13:125.
BCMA
STABLE OF TREATMENT FINDING YOUR GAIT GOING THE DISTANCE
CAR T and Bispecific Antibodies: Unique Side Effects
Fever Confusion
Weakness
Fatigue
CRS
Headache
CRS is a common but usually mild side effect
Nausea / vomiting
Diarrhea Shortness of Breath
42
CRS = cytokine release syndrome. Oluwole OO, Davila ML. J Leukoc Biol. 2016;100:1265-1272. June CH, et al. Science. 2018;359:1361-1365. Brudno JN, Kochenderfer JN. Blood. 2016;127(26):3321-3330. Brudno JN, Kochenderfer JN. Blood Rev. 2019:34:45-55. Shimabukuro-Vornhagen, et al. J Immunother Cancer. 2018;6:56. Lee DW, et al. Biol Blood Marrow Transplant. 2019;25:625-638.
CAR T and Bi-specific Antibodies: Unique Side Effects
Headach e Confusio Encephalop athy n Seizures NEUROTOXICITY
Hallucinati ons
Tremors Facial nerve palsy
43
Altered wakefuln ess
Apraxia
STABLE OF TREATMENT FINDING YOUR GAIT GOING THE DISTANCE
Neurotoxicity is a rare but serious side effect
Ataxia
CRS = cytokine release syndrome; ICANS = immune effector cell–associated neurotoxicity syndrome; ICE = Immune Effector Cell Encephalopathy screening tool; MRI = magnetic resonance imaging. Brudno JN, Kochenderfer JN. Blood. 2016;127(26):3321-3330. Lee DW, et al. Biol Blood Marrow Transplant. 2019;25:625-638.
STABLE OF TREATMENT FINDING YOUR GAIT GOING THE DISTANCE
Infection Awareness & Prevention
Infection Prevention Tips Good personal hygiene (skin, oral)
Environmental control (wash hands, avoid crowds and sick people, etc)
Growth factor (Neupogen [filgrastim])
Immunizations (NO live vaccines)
Medications (antibacterial, antiviral)
As recommended by your health care team
COVID: The Best Way to Prevent Illness Is to Avoid Being Exposed to the Virus
Spread mainly through respiratory droplets that are produced by cough, sneezing and talking. More droplets with louder talking, yelling, singing 44
Get COVID Vaccine + Booster: Excellent protection against severe disease, but vaccine effectiveness may be lower in people with compromised immune systems Wear a High-quality Mask: Respiratory droplets can spread disease; a high-quality mask can prevent exposure to airborne viral particles Avoid Crowds & Sick People Physical Distance & Outdoors: Close contact and indoor locations increases risk of spread Wash Your Hands: Less common to get from a hard surface
CDC website. How to Protect Yourself & Others. Accessed June 17, 2021.
• Report fever of more than 100.4°F, shaking chills even without fever, dizziness, shortness of breath, low blood pressure to HCP as directed. • Compromised immune function comes from multiple myeloma and from treatment. • Infection is serious for myeloma patients!
STABLE OF TREATMENT FINDING YOUR GAIT GOING THE DISTANCE
Supportive Care to Address Side Effects
• • •
It is important to stay on myeloma treatment to control myeloma cells and get the most from each treatment. Responses deepen over time. Talk to your team if side effects are bothersome. Your team may be able to help, but only if they know. DVT/PE Prevention
Bone Health
Blood thinners Ex: Aspirin, DOACs
Bone Strengthening Agents Calcium Vitamin D
Non-medication Therapies
Compression stockings
Radiation Surgery Immobilization Physical therapy
Lifestyle Options
Activity Stop smoking Weight loss
Supportive Medications
45
Don’t change horses midstream
Activity
Renal Health
Infection Prevention
Peripheral Neuropathy
GI Symptoms
Med dose reduction Avoid harmful meds
Antibacterial Antiviral Antifungal IVIG GCSF
Anti-depressants Anti-neuroleptic Analgesia Vitamins Dose adjustments
Anti-nausea Anti-diarrheal Laxatives & stool softners Fiber-binding agents
Dialysis
Masking
Massage Acupuncture Cocoa Butter Scrambler therapy
Dietary choices Relaxation
Hydration
Handwashing Avoid crowds & sick people Monitor for fever COVID precautions
Activity Diabetes management
Avoid greasy foods Activity Hydration
STABLE OF TREATMENT FINDING YOUR Symptoms of Multiple Myeloma GAIT GOING THE DISTANCE A meta-analysis identified the most common patient-reported symptoms and their impact on QOL. Symptoms
were present at all stages of disease. Symptoms resulted from both disease and treatment, including transplant, and were in these categories:
Physical
• Fatigue • Constipation • Pain • Neuropathy • Impaired Physical Functioning • Sexual Dysfunction
46
Ramsenthaler, et al. 2016. https://doi.org/10.1111/ejh.12790.
Psychological
• Depression • Anxiety • Sleep Disturbance • Decreased Cognitive Function • Decreased Role & Social Function
Financial
• Financial burden (80%) • Financial toxicity (43%)
Steroids: The Good, The Bad, The Ugly
Steroid Synergy
• Steroids are a backbone and work in
combination to enhance myeloma therapy
Managing Steroid Side Effects
• Consistent schedule (AM vs. PM) • Take with food • Stomach discomfort: Over-the-counter
or prescription medications • Medications to prevent shingles, thrush, or other infections
Steroid Side Effects • Irritability, mood swings, depression
• Difficulty sleeping (insomnia),
fatigue
• Blurred vision, cataracts
• Flushing/sweating
• Increased risk of infections, heart
• Stomach bloating, hiccups,
disease
• Muscle weakness, cramping
• Increased blood pressure, water
retention
47
STABLE OF TREATMENT FINDING YOUR GAIT GOING THE DISTANCE
heartburn, ulcers, or gas
• Weight gain, hair thinning/loss, skin
rashes
• Increased blood sugar levels,
diabetes
Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M, Greipp PR, Eastern Cooperative Oncology Group (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11(1):29–37. King T, Faiman B. Steroid-Associated Side Effects: A Symptom Management Update on Multiple Myeloma Treatment. Clin J Oncol Nurs. 2017 Apr 1;21(2):240-249. doi: 10.1188/17.CJON.240-249. PMID: 28315528.
STABLE OF TREATMENT FINDING YOUR GAIT GOING THE DISTANCE
GI Symptoms: Prevention & Management
Diarrhea may be caused by medications
Constipation may be caused by medications and
Avoid caffeinated, carbonated, or heavily sugared beverages
Increase fiber • Fruits, vegetables, high fiber whole grain foods • Fiber binding agents – Metamucil®, Citrucel®, Benefiber®
and supplements
Take anti-diarrheal medication if recommended
supplements
Fluid intake can help with both diarrhea and constipation and helps kidney function. Discuss GI issues with health care providers to identify causes and make adjustments to medications and supplements. 48
Smith LC, et al. CJON.2008;12(3)suppl:37-52. Faiman B. CJON. 2016;20(4):E100-E105.
Pain Prevention and Management
Pain can significantly compromise quality of life
STABLE OF TREATMENT FINDING YOUR GAIT GOING THE DISTANCE
Sources of pain include bone disease, neuropathy and medical procedures • Management – – – – –
Prevent pain when possible • Bone strengtheners to decrease fracture risk; anti viral to prevent shingles; sedation before procedures Interventions depends on source of pain May include medications, activity, surgical intervention, radiation therapy, etc Complementary therapies (Mind-body, medication, yoga, supplements, acupuncture, etc) Scrambler therapy for neuropathy
Tell your health care provider about any new bone pain or chronic pain that is not adequately controlled. 49
Faiman B, et al. CJON. 2017;21(5)suppl:19-36.
Peripheral Neuropathy Management
Peripheral neuropathy:
Damage to nerves in extremities (hands, feet, or limbs) • Numbness • Tingling • Prickling sensations • Sensitivity to touch • Burning and/or cold sensation • Muscle weakness
Prevention / management: • Bortezomib once-weekly or subcutaneous
administration • Massage area with cocoa butter regularly • Supplements: – B-complex vitamins (B1, B6, B12) – Folic acid, and/or amino acids but do not take on day of Velcade® (bortezomib) infusion • Safe environment: rugs, furnishings, shoes
Report symptoms of peripheral neuropathy early to your health care provider; nerve damage from neuropathy can be permanent if unaddressed.
50
Faiman B, et al. CJON. 2017;21(5)suppl:19-36. Tariman, et al. CJON.2008;12(3)suppl:29-36.
STABLE OF TREATMENT FINDING YOUR GAIT GOING THE DISTANCE
If neuropathy worsens, your provider may: • Change your treatment • Prescribe oral or topical pain
medication • Suggest physical therapy
Why the Long Face?
98.8%
Fatigue
STABLE OF TREATMENT FINDING YOUR GAIT GOING THE DISTANCE
Fatigue is the most commonly reported symptom. Sources include anemia, pain, reduced activity, insomnia, treatment toxicity, bone marrow suppression
Anxiety
Depression
>35%
~25%
of patients
of patients
Often, people do not share these symptoms with their provider. Talk to your provider about symptoms that are not well controlled or if you have thoughts of self harm. Help is available. 51
Rest and Relaxation Contribute to Good Health
• Adequate rest and sleep are essential to a healthful lifestyle Shortened and disturbed sleep increase risk of Heart related death Increase anxiety Weakened immune system Worsened pain Falls and personal injury • Things that can interfere with sleep – Medications: steroids, stimulants, herbal supplements – Psychologic: fear, anxiety, stress – Physiologic: sleep apnea, heart issues, pain – – – – – –
52
STABLE OF TREATMENT FINDING YOUR GAIT GOING THE DISTANCE Sleep hygiene is necessary for quality nighttime sleep and
daytime alertness – Engage in exercise but not too near bedtime – Increase daytime natural light exposure – Avoid daytime napping – Establish a bedtime routine - warm bath, cup of warm milk or tea • Associate your bed ONLY with sleep • Sleep aid may be needed – Avoid before bedtime: • Caffeine, nicotine , alcohol and sugar • Large meals and especially spicy, greasy foods • Computer screen time
Rod NH et al 2014. PloS one. 9(4):e91965; Coleman et al. 2011. Cancer Nurs. 34(3):219-227.National Sleep Foundation. At: http://sleepfoundation.org/ask-the-expert/sleep-hygiene Mustian et al. Journal of clinical Oncology. Sep 10 2013;31(26):3233-3241; Stan DL, et al. Clin J Oncol Nurs. Apr 2012;16(2):131-141; Zeng Y et al., Complementary therapies in medicine. Feb 2014;22(1):173-186.
Financial Burden
• Financial burden comes from • Medical costs
Premiums Co-payments Travel expenses Medical supplies • Prescription costs • Loss of income – Time off work or loss of employment – Caregiver time off work – – – –
• – – – –
STABLE OF TREATMENT FINDING YOUR GAIT GOING THE DISTANCE Funding and assistance may be available
Federal programs Pharmaceutical support Non-profit organizations Websites: • Medicare.gov • SSA.gov • LLS.org • Rxassist.org • NeedyMeds.com • HealthWellFoundation.org • Company-specific website
Contact the Social Services department at your hospital or clinic to talk to a social worker for assistance. 53
Finding Your Gait Be an empowered patient; engage in your care
54
STABLE OF TREATMENT FINDING YOUR GAIT GOING THE DISTANCE
YOU are central to the care team Be empowered Ask questions, learn more Participate in decisions Communicate with your team Understand the roles of each team member and who to contact for your needs Participate in support network
Pharmacist
Don’t Ride Alone
General Hem/Onc
STABLE OF TREATMENT FINDING YOUR GAIT GOING THE Myeloma DISTANCE
Specialist
Primary Care Provider (PCP) You and Your Care Partner(s)
Support Network Subspecialists
55
Allied Health Staff
STABLE OF TREATMENT FINDING YOUR GAIT GOING THE DISTANCE
IMF: Knowledge Is Power
Website: http://myeloma.org
Download or order at myeloma.org
56
IMF InfoLine: 1-800-452-CURE | 9am to 4pm PST
IMF Videos
eNewsletter: Myeloma Minute
Going the Distance Healthful living, infection prevention, renal and bone health
57
STABLE OF TREATMENT FINDING YOUR GAIT GOING THE DISTANCE
Healthful Living Strategies: Prevention Maintain renal health • Myeloma management • Hydration • Avoid renally-toxic medications – Dose adjust to renal function • Diabetes management
Protect your bones Nutrition, Calcium + D supplement Weight-bearing activity and/or walking Bone strengthening agents
Preventative health care Health screenings, vaccinations Prevent falls, injury, infection Stop smoking Dental care
Maintain a healthy weight Nutrition Activity / exercise
STABLE OF TREATMENT FINDING YOUR GAIT GOING THE DISTANCE
Manage stress • Rest, relaxation, sleep hygiene • Mental health / social engagement • Complementary therapy
An ounce of prevention is worth a pound of cure. Benjamin Franklin
58
Faiman B, et al. CJON. 2017;21(5)suppl:19-36. Dimopoulous M, et al. Leukemia. 2009;23(9):1545-56. Brigle K, et al. CJON. 2017;21(5)suppl:60-76. Faiman B, et al. CJON. 2017;21(5)suppl:19-36. Faiman B, et al. CJON. 2011;15suppl:66-76. Miceli TS, et al. CJON. 2011;15(4)suppl:9-23.
Healthful Living Strategies: Keep Active Movement therapies can reduce stress, promote sleep
Yoga, Pilates, Tai Chi • Shown to improve sleep and sleep quality • Improved quality of life & mood
Do:
STABLE OF TREATMENT FINDING YOUR GAIT GOING THE DISTANCE
• Keep a log or journal of your activity • Notify your healthcare provider about sudden onset of pain, progressive weakness, headaches, blurred vision, numbness, and tingling • Dehydration can lead to low blood pressure, falls • Consider weightlifting limits Do Not:
• Overdo it • Force exercise • Try things without discussing with provider
Myeloma bone disease may affect your ability to do certain movement activities. Review your activity interests with your health care provider! 59
Boullosa DA, et al., Jul 2013;45(7):1223-1228. Faiman B et al., Clinical Journal of Oncology Nursing. 2008;12(0):53-62; Rome S et al., Clin J Oncol Nurs. Aug 2011;15 Suppl:41-52; Miceli T et al., Clinical Journal of Oncology Nursing. 2011;15:9-23; Coleman EA et al.,Oncol Nurs Forum. May 2008;35(3):E53-61.
Q&A
with panel
60
BREAK 61
61
STABLE OF TREATMENT FINDING YOUR GAIT ENJOYING THE RIDE
Agenda after break
all times are listed in Pacific Time Zone
7:05 – 7:30 PM
Frontline Therapy Rafat Abonour, MD, University of Indiana, Indianapolis, IN
7:30 – 7:45 PM
Q&A with Panel
7:45 – 8:15 PM
Relapse & Immune Therapies Ajai Chari, MD, University of California San Francisco
8:15 – 8:30 PM
Q&A with Panel
8:30 PM
Closing Remarks
Upfront Therapy for Multiple Myeloma Rafat Abonour, M.D. Harry and Edith Gladstein Professor of Cancer Research Professor of Medicine, Pathology and Laboratory Medicine Director, Multiple Myeloma, Waldenstrom's Disease and Amyloidosis Program Indiana University School of Medicine
Treatment Goals •
•
Symptom Control • Ameliorate pain and other disease-related symptoms • Prevent further organ damage • Preserve and improve performance status and quality of life Disease Response and Survival • Rapid myeloma eradication. • Minimize treatment-related toxicity • Prolong survival – Overall Survival
Depth of Response Influence Time to Relapse Getting rid of myeloma is a good thing
PR=partial response, VGPR=very good partial response, CR=complete remission, MRD= minimal residual disease
Minimal Residual Disease (MRD) Testing • MRD is emerging as an important marker of lasting clinical benefit • MRD can be tested: − Using flowcytometry. Sensitive at 10-5 and can be done
anytime on bone marrow samples and does not require knowing what the patient myeloma sequences were at diagnosis
− Using next generation sequences Sensitive at 10-6 but
require knowing what the patient myeloma sequences were at diagnosis.
MRD Strongly Predicts outcomes If patient achieved Negative MRD their myeloma stay under control longer and they live longer
Munshi et al. Blood Advances 2020; 4:23
MRD May Abrogate Other Risk Factors High risk patients achieving MRD- do better Opportunity for de-escalation
Need to employ new approaches
Goicochea I et al. Blood 2021;137:49
PETHEMA/GEM2012 (MRD < 2 x 10-6)
The Evolution of Myeloma Therapy Many New Drugs and Many New Combinations Now
VD Rev/Dex CyBorD VTD VRD SCT KRD Tandem ASCT (?) D-VMP DRD Front line treatment
Induction
New
D-VRD Isa-VRD D-KRD Isa-VRD
Nothing Thalidomide? Bortezomib Ixazomib Lenalidomide Combinations Maintenance
Consolidation
Post consolidation
“more” induction?
Daratumumab? Carfilzomib? Lenalidomide + PI
ASCT, autologous stem cell transplant; CAR, chimeric antigen receptor; Cy, cyclophosphamide; ddaratumumab; D/dex, dexamethasone; isa, isatuximab; K, carfilzomib; M, melphalan; PD-L1, programmed death ligand-1; PI, proteasome inhibitor; Rev, lenalidomide; V, bortezomib
Panobinostat Bortezomib Lenalidomide Daratumumab Ixazomib Carfilzomib Pomalidomide Elotuzumab Isatuximab Selinexor Belantamab mafodotin Melphalan flufenamide Idecabtagene Relapsed autoleucel
Rescue
CAR T Cell Therapy Bispecific/Trispecific Antibodies Cell Modifying Agents Venetoclax? PD/PDL-1 Inhibition? Multiple small molecules ++++++++
How does your doctor decide?
Upfront therapy
• Combination therapy continues to prove superiority in providing long remission and long survival. • The patient is at good place as options are becoming more prevalent. • Lenalidomide, bortezomib and dexamethasone continues to be an effective regimen. • Daratumumab in combination with lenalidomide is an excellent option for “frail patient” • But wait there are more to come
How did we start? Is three drugs better than two?
Three drugs better in some Patients Myeloma under control longer and you live longer
SWOG 0777
The Newer Three Drugs Regimen Phase III MAIA Study Design: Adding daratumumab to lenalidomide and steroid regimen
Transplant-not preferred NDMM ECOG PS 0-2 CrCl ≥30 mL/min (N = 737)
1:1
Daratumumab 16 mg/kg IVa + Lenalidomide 25 mg/d PO, d 1-21 + Dexamethasone 40 mg/w PO or IV (n = 368)
Lenalidomide 25 mg/d PO, d 1-21 + Dexamethasone 40 mg/w PO or IV (n = 369)
Primary endpoint: PFS Secondary endpoints: CR, VGPR, MRD negativity, ORR, OS, safety
28-day cycles until PD
Median age: 73 years (45-90) 99% of patients age ≥ 65 years
Stratification: • ISS (I, II, III) • Region (N America vs other) • Age (<75 y vs ≥75 y) Facon T, et al. 2018 ASH. Abstract LBA2. Facon T, et al. N Engl J Med. 2019;380:2104-2115
aQW cycles 1-2, Q2W cycles 3-6, Q4W cycle ≥7.
Phase III MAIA: better response rates, and Sustained MRD-Negativity Rates
Median follow-up: 64.5 months Daratumumab favored in most subgroups, including for both PFS and OS endpoints Reduced risk of progression or death with MRD negativity in both arms Responses deepened over time
Kumar S, et al. ASH 2022. Poster 4559. Facon T, et al. EHA 2021. Abstract LB1901. Facon T, et al. Lancet Oncol. 2021;22:1582-1596
MAIA: Is It Safe to Use 3 Drugs TEAE, %
Daratumumab + Rd (n = 364)
Rd (n = 365)
Any Grade
Grade 3/4
Any Grade
Grade 3/4
57 35 19 18
50 12 7 15
42 38 19 12
35 20 9 11
57 41 40 38 34 32 32 23 12
7 2 8 2 3 4 1 14 6
46 36 28 29 26 25 23 13 13
4 <1 4 <1 3 4 <1 8 6
41
3
--
--
Hematologic Neutropenia Anemia Thrombocytopenia Lymphopenia Nonhematologic Diarrhea Constipation Fatigue Peripheral edema Back pain Asthenia Nausea Pneumonia DVT and/or pulmonary embolism Infusion-related reaction Invasive second primary malignancy
3
4
TEAE resulting in death
7
6
No new safety concerns were identified with longer follow up Facon T, et al. 2018 ASH. Abstract LBA2; Facon T, et al. N Engl J Med. 2019;380:2104-2115. Facon T, et al. EHA 2021. Abstract LB1901. Facon T, et al. Lancet Oncol. 2021;22:1582-1596. Kumar S, et al. ASH 2022. Poster 4559.
Can you use three drugs before transplant!! IFM 2009: RVD ± ASCT (The French version) Transplant-preferred NDMM RVD x 3 cycles, ASCT collection, Cy 3 g/m2 • RVD cycles 4-8
RVD x 3 cycles, ASCT collection, Cy 3 g/m2 • ASCT with MEL 200 • RVD cycles 4, 5
Lenalidomide 10-15 mg daily x 12 months
36 mo
mPFS (44 mo fu)1
50 mo
35 mo
mPFS (90 mo fu)2
47.3 mo
60.2%
8-y OS (90 mo fu)2
62.2%
44-mo follow up
PFS=Progression free survival, OS= overall survival Attal M, et al. N Engl J Med. 2017;376;1311-20. 2. Perrot A, et al. ASH 2020
IFM 2009 Study of RVD± ASCT: PFS by MRD Status
Perrot A, et al. ASH 2020. Abstract 143.
Why is this French Study Important! Downsides of Continuous Maintenance Therapy
IFM 2009
No therapy
Deferring Lenalidomide for 7 years: -”Saving” of $1.5 million! -Avoid ~3.5% absolute increase in risk of SPM
Most visits patients have not progressed in 7years despite no therapy Perrot A et al. ASH meeting 2020
-Avoid dozens of extra lab checks/MD -Avoid diarrhea, fatigue, rash -Avoid “daily reminder I have cancer”
DISCLOSURE NOT ALL MYELOMA EXPERTS AGREE ON THIS
Why not 4 drugs regimen!! Randomized Phase 2 GRIFFIN Trial of DRVd vs RVd with transplant
Stratification factors •ISS disease stage (I, II, or III) •CrCl (30-50 or >50 mL/min)
Induction: Cycles 1-4
Consolidation: Cycles 5-6c
Maintenance: Cycles 732
D-RVd
D-RVd
D-R
D: 16 mg/kg IV Days 1, 8, 15 R: 25 mg PO Days 1-14 V: 1.3 mg/m2 SC Days 1, 4, 8, 11 d: 20 mg PO Days 1, 2, 8, 9, 15, 16
RVd
R: 25 mg PO Days 1-14 V: 1.3 mg/m2 SC Days 1, 4, 8, 11 d: 20 mg PO Days 1, 2, 8, 9, 15, 16 21-day cycles
TRANSPLANT
Key eligibility criteria • Transplant-preferred NDMM • 18-70 years of age • ECOG PS score 0-2 • CrCl ≥30 mL/mina
1:1 RANDOMIZATION
• 35 sites in the United States with enrollment between December 2016 and April 2018
D: 16 mg/kg IV Day 1 R: 25 mg PO Days 1-14 V: 1.3 mg/m2 SC Days 1, 4, 8, 11 d: 20 mg PO Days 1, 2, 8, 9, 15, 16
RVd
R: 25 mg PO Days 1-14 V: 1.3 mg/m2 SC Days 1, 4, 8, 11 d: 20 mg PO Days 1, 2, 8, 9, 15, 16 21-day cycles
D: 16 mg/kg IV Day 1 Q4W or Q8Wd R: 10 mg PO Days 1-21 Cycles 7-9; 15 mg PO Days 1-21 Cycles 10+
R
R: 10 mg PO Days 1-21 Cycles 7-9; 15 mg PO Days 1-21 Cycles 10+
Endpoints and statistical assumptions Primary endpoint: • sCR rate (by end of consolidation); 1-sided alpha of 0.10 • 80% power to detect 15% improvement (50% vs 35%), N = 200 Other endpoints: • Rates of MRD negativitye (NGS), ORR, ≥VGPR, CR, PFS, OS
28-day cycles
Stem cell mobilization with G-CSF ± plerixaforb; High-dose therapy (melphalan 200 mg/m2)
• Median age ~60; ISS3 14%, High risk 15% • Lower ASCT rate in RVd arm due to early discontinuations
ECOG PS, Eastern Cooperative Oncology Group performance status; CrCl, creatinine clearance; IV, intravenous; PO, oral; SC, subcutaneous; G-CSF, granulocyte colony-stimulating factor; D-R, daratumumab plus lenalidomide; Q4W, every 4 weeks; Q8W, every 8 weeks; NGS, next-generation sequencing; ORR, overall response rate; VGPR, very good partial response; CR, complete response; PFS, progression-free survival; PFS2, PFS on next subsequent line of therapy; OS, overall survival. aLen dose adjustments were made for pts w/ CrCl ≤50 mL/min. bCyclophosphamide-based mobilization was permitted if unsuccessful. cConsolidation was initiated 60 to 100 days post-transplant. dProtocol amendment 2 allowed for the option to dose DARA Q4W based on pharmacokinetic results from study SMM2001 (NCT02316106). eTo measure MRD negativity at a minimum threshold of 10–5, bone marrow aspirates were collected at first evidence of suspected CR or sCR (including patients with ≥VGPR and suspected DARA interference), after induction but before stem cell collection, at the post-transplant consolidation disease evaluation, and at 12 mo and 24 mo (±3 weeks) of maintenance therapy.
Sborov D, et al. IMS Annual Meeting 2022.
GRIFFIN Final Analysis: PFS in the ITT Population (Median Follow-up: 49.6 Mo) • Median PFS was not reached in either group • PFS was longer for D-RVd/D-R versus RVd/R, with a clinically meaningful 55% reduction in the risk of disease progression or death • Regardless of R therapy continuation after end of study treatment, a PFS benefit was observed in the D-RVd group versus the RVd group • OS not reached/not mature; longer follow up would be needed to evaluate; 4year OS: 92.7% D-RVd vs 92.2% RVd Sborov D, et al. IMS Annual Meeting 2022.
GRIFFIN: Rates of Durable MRD Negativity (10-5) Lasting ≥ 6 Months or ≥ 12 Months—D-RVd vs RVd
Labauch JP, et al. ASH 2021. Abstract
Summary: Upfront therapy with SCT 350 vs 350
DETERMINATIO N RVd-SCT vs RVd + R to PD 365 vs 357
90
76
50.9
49.6
N/A 78 vs 69 N/A
98 vs 95 83 vs 80 33 vs 28 68 vs 46 1.53 (1.23-1.91) P < .001
97 vs 94 89 vs 87 46 vs 44 NR vs 55.3 0.88 (0.64-1.22) P = .45
99 vs 92 96 vs 77 67 vs 48 NR vs NR 0.45 (0.21-0.95) P = .0324
NR vs NR 1.10 (0.73-1.65) P > .99
NR vs NR 0.94 (0.54-1.63) P = .81
NR vs NR 0.90 (0.31-2.56) P = 0.8408
IFM 2009 RVd-SCT vs RVd + 1y Ra Total N Median follow up, mo ORR, % ≥VGPR, % sCR, % mPFS, mo HR (95% CI) P
47 vs 35 0.70 (0.59-0.83) P = .0001
OS HR
NR vs NR 1.03 (0.8-1.32)
FORTE KRd-SCT vs KRdb
Griffin SCT DaraVRd +2 y DR vs VRd + 2 y Rc
158 vs 157
104 vs 103
a. Results post 1 y maintenance. b. Results post induction, intensification, and consolidation. c. Results post 2 y maintenance.
NR, not reached; NS, no significant difference. Attal et al. N Engl J Med. 2017; Richardson P, et al. N Engl J Med. Jun 5 2022; Perrot ASH 2020; Gay F, et al. Lancet Oncol. 2021;22:1705-1720. Gay F, et al ASCO 2019/ASH 2020; Sborov D, et al. IMS 2022.
Can we use Sustain MRD to guide our therapy?!! Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation-Final Primary Endpoint Analysis of the MASTER Trial
Luciano J. Costa1, Saurabh Chhabra2, Natalie S. Callander, MD3 , Eva Medvedova4, Bhagirathbhai Dholaria5, Rebecca Silbermann4, Kelly Godby1, Binod Dhakal2, Susan Bal1, Smith Giri1, Anita D’Souza2, Timothy Schmidt3, Aric Hall3, Pamela Hardwick1, Robert F. Cornell5, Parameswaran Hari2 1- University of Alabama at Birmingham; 2- Medical College of Wisconsin; 3- University of Wisconsin at Madison; 4- Oregon Health and Science University; 5- Vanderbilt University
COMMIT- Academic Consortium to Overcome Multiple Myeloma through Innovative Trials
Treatment decision based on response Dara-KRd Daratumumab 16 mg/m2 days 1,8,15,22 (days 1,15 C 3-6; day 1 C >6) Carfilzomib (20) 56 mg/m2 Days 1,8,15 Lenalidomide 25 mg Days 1-21 Dexamethasone 40mg PO Days 1,8,15,22
MRD assessment by NGS *24 and 72 weeks after completion of therapy
Consolidation
Dara-KRd x 4
Dara-KRd x 4
2nd MRD (-) (<10-5)
2nd MRD (-) (<10-5)
MRD→
MRD→
Dara-KRd x 4
AHCT
Consolidation
MRD→
Induction
MRD→
• • • •
Lenalidomide Maintenance
2nd MRD (-) (<10-5)
”MRD-SURE” -Treatment-free observation and MRD surveillance*
MASTER trial
Progression-Free and Overall Survival Based on Presence of High-Risk Features
2-year PFS
0 HRCA
91%
1 HRCA
97%
2+ HRCA
58%
2-year OS
0 HRCA
96%
1 HRCA
100%
2+ HRCA
76%
High risk cytogenetics abnormalities. HRCA = gain/amp 1q, t(4;14), t(14;16), t(14;20) or del(17p)
MASTER
Conclusions • NGS-MRD response-adapted therapy is feasible in ~96% of patients in multi center setting – 72% reaching MRD-SURE. • Patients with standard and high-risk NDMM have similar depth of response and low risk of MRD resurgence or progression when treated with Dara-KRd/AHCT and MRDadapted treatment cessation. • Quadruplet therapy and achievement of confirmed MRD (-) responses enables the exploration of treatment cessation and “MRD-SURE” as alternative to continuous therapy.
Effective novel consolidative strategies should be explored to clear MRD and improve outcomes in patients with ultra-high-risk MM MASTER trial
Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone as Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma: The Phase III GMMG-HD7 Trial Hartmut Goldschmidt1,2, Elias K. Mai1, Eva Nievergall1, Roland Fenk3, Uta Bertsch1,2, Diana Tichy4, Britta Besemer5, Jan Dürig6, Roland Schroers7, Ivana von Metzler8, Mathias Hänel9, Christoph Mann10, Anne Marie Asemissen11, Bernhard Heilmeier12, Stefanie Huhn1, Katharina Kriegsmann1, Niels Weinhold1, Steffen Luntz13, Tobias A. W. Holderried14, Karolin Trautmann-Grill15, Deniz Gezer16, Maika Klaiber-Hakimi17, Martin Müller18, Cyrus Khandanpour19, Wolfgang Knauf20, Markus Munder21, Thomas Geer22, Hendrik Riesenberg23, Jörg Thomalla24, Martin Hoffmann25, Marc-Steffen Raab1, Hans J. Salwender26, Katja C. Weisel11 for the German-speaking Myeloma Multicenter Group (GMMG) 1Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany; 2National Center for Tumor Diseases Heidelberg, Heidelberg, Germany;
3Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany; 4Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany; 5Department of Internal Medicine II, University Hospital Tübingen, Tübingen, Germany; 6Department for Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany;
7Medical Clinic, University Hospital Bochum, Bochum, Germany; 8Department of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany;
9Department of Internal Medicine III, Clinic Chemnitz, Chemnitz, Germany; 10Department for Hematology, Oncology and Immunology, University Hospital Gießen and Marburg, Marburg, Germany;
11Department of Oncology, Hematology and BMT, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 12Clinic for Oncology and Hematology, Hospital Barmherzige Brueder Regensburg, Regensburg,
Germany; 13Coordination Centre for Clinical Trails (KKS) Heidelberg, Heidelberg, Germany; 14Department of Oncology, Hematology, Immuno-Oncology and Rheumatology, University Hospital Bonn, Bonn, Germany; 15Department of Internal Medicine I, University Hospital Dresden, Dresden, Germany; 16Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany; 17Clinic for Hematology, Oncology and Palliative Care, Marien Hospital Düsseldorf, Düsseldorf, Germany; 18Clinic for Hematology, Oncology and Immunology, Klinikum Siloah Hannover, Hannover, Germany; 19Medical Clinic A, University Hospital Münster, Münster, Germany; 20Center for Hematology and Oncology Bethanien, Frankfurt am Main, Germany; 21Department of Internal Medicine III, University Hospital Mainz, Mainz, Germany; 22Department of Internal Medicine III, Diakoneo Clinic Schwäbisch-Hall, Schwäbisch-Hall, Germany; 23Hematology/Oncology Center, Bielefeld, Germany; 24Hematology / Oncology Center, Koblenz, Germany; 25Medical Clinic A, Clinic Ludwigshafen, Ludwigshafen, Germany; 26Asklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, Hamburg, Germany
ASH 2021; Final Abstract Code: 463
Primary endpoint: MRD negativity at the end of induction phase Induction phase (3 x 6-week cycles) Isa + RVd HDT + ASCT RVd After Cycle 3
Screenin MRD (bone marrow aspirate) g
Primary endpoint: • MRD negativity at the end of induction treatment (NGF, sensitivity 10-5) stratified according to R-ISS
Maintenance phase (4-week cycles) Randomization
NDMM N=662
Randomization 1:1
HD7
Aft er HD T
Isa + R
3 years or PD
R After 12 month s
After 24 months
End of study
Secondary endpoints: • CR after induction • Safety Data cut-off: • April 2021 ASCT, autologous stem cell transplant; CR, complete response; d, dexamethasone; HDT, high-dose therapy; Isa, isatuximab; MRD, minimal residual disease; NDMM, newly diagnosed multiple myeloma; NGF, next-generation flow; PD, progressive disease; R, lenalidomide; R-ISS, Revised International Staging System; Te, transplant eligible; V, bortezomib 1. ClinicalTrials.gov: NCT03617731
8 9
HD7
First primary endpoint, end of induction MRD negativity by NGF (10-5), was met in ITT analysis Patients with MRD negativity at the end of induction therapy OR 1.83 (95% CI 1.34–2.51) P<0.001*
60% 40%
50.1%
IsaRVd
35.6%
20% 0% Low number of not assessable/missing† MRD status: Isa-RVd (10.6%) and RVd (15.2%)
Isa-RVd is the first regimen to demonstrate a rapid and statistically significant benefit from treatment by reaching a MRD negativity of 50.1% at the end of induction and to show superiority vs. RVd in a Phase 3 trial *P value derived from stratified conditional logistic regression analysis †Missing NGF-MRD values were due to either patients’ loss to follow-up during induction therapy or to missing bone marrow samples or technical failures in measurement counted as non-responders, i.e. NGF-MRD positive CI, confidence interval; d, dexamethasone; Isa, isatuximab; ITT, intent-to-treat; MRD, minimal residual disease; NGF, next-generation flow; OR, odds ratio; R, lenalidomide; V, bortezomib
9 0
Response rates after induction therapy HD7
P=0.02* P<0.001*
100%
77.3%
80% P=0.15*
60% 40% 20% 0%
P=0.46*
41.7% 36.2%
CR
>nCR ≥
24.2% 21.6%
Isa-RVd† RVd
90.0% 83.6%
60.5%
>VGPR ≥
>PR ≥
Although the rates of CR after induction therapy did not differ between the Isa-RVd and RVd arms, there was a significant increase in ≥VGPR rates and ORR with Isa-RVd *P values derived from Fisher’s exact test †Data adjusted per M-protein interference CR, complete response; d, dexamethasone; Isa, isatuximab; nCR; near-complete response; ORR, overall response rate; PR, partial response; R, lenalidomide; V, bortezomib; VGPR, very good partial response
9 1
Addition of Isa to RVd had limited impact on safety profile
HD7
AEs CTCAE grade ≥3, n (%)
Isa-RVd (n=330)
RVd (n=328)
AEs CTCAE grade ≥3, n (%)
Any AE
210 (63.6)
201 (61.3)
Specific hematologic AE (PT)
Any serious AE (any grade)
115 (34.8)
119 (36.3)
Deaths
4 (1.2)
8 (2.4)
nia†
Investigations* (SOC)
79 (23.9)
77 (23.5)
Blood and lymphatic system disorders (SOC)
85 (25.8)
Infections and infestations (SOC)
Isa-RVd (n=330)
RVd (n=328)
87 (26.4)
30 (9.1)
Lymphopenia
48 (14.5)
65 (19.8)
55 (16.8)
Anemia
13 (3.9)
20 (6.1)
43 (13.0)
34 (10.4)
Thrombocytopenia
21 (6.4)
15 (4.6)
Nervous system disorders (SOC)
28 (8.5)
33 (10.1)
Gastrointestinal disorders (SOC)
27 (8.2)
31 (9.5)
Peripheral neuropathy
25 (7.6)
22 (6.7)
Metabolism and nutrition disorders (SOC)
12 (3.6)
26 (7.9)
Thromboembolic events
5 (1.5)
9 (2.7)
Leukocytopenia/Neutrope
Specific non-hematologic AE (PT)
Infusion-related reactions (1.2) A comparable number of patients discontinued induction therapy due to AEs in4 the Isa-RVd arm vs. RVd arm ‡
*SOC considered as “Investigations” as defined by the CTCAE †Includes five episodes of febrile neutropenia during induction: Isa-VRd (n=3) vs. VRd (n=2) ‡Infusion-related reactions of CTCAE grade 2 or higher in the Isa-RVd arm were n=42 (12.7%) AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; d, dexamethasone; Isa, isatuximab; NA, not applicable; PT, preferred term; R, lenalidomide; SOC, system organ class; V, bortezomib
NA
9 2
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma Lisa B. Leypoldt et al
JCO Published online September 27, 2023. PMID: 37753960
Isatuximab RVD in High-risk patient for transplant eligible (TE) and Transplant ineligible (TNE)
Isatuximab RVD in High-risk patient for transplant eligible (TE) and Transplant ineligible (TNE)
Upfront Therapy Status..Evolving • • • • • • •
Adding a CD38 antibody to VRD or KRD is feasible with limited incremental toxicity Depth of response is improved, including MRD negativity MRD will be an even more important measure going forward There is a trend to improved PFS This may overcome the high-risk feature of some patients Ultra high-risk disease remains challenging to treat with current strategies What about transplant?? It is still part of most upfront studies.
Is This The future: MASTER 2 The Dream Trial
Sequential Therapy in Multiple Myeloma Guided by MRD Assessments Consolidation
Maintenance
X 3 cycles
MRD (-) randomization
CD38MoAbR x 1 year
CD38MoAbR x 1 year
AHCT Quadruplet x 6 cycles
MRD (+) randomization
AHCT *MRD-SURE – Treatment-free observation and MRD surveillance
← MRD2→
R
T-cell Redirecting therapy
T-cell Redirecting therapy
←MRD1x →
AHCT
MRD1 →
Arm M
Sustained MRD Negativity
CD38MoAb-R X3 cycles
MRDSURE* ← MRD3→
R
← MRD2→
Stem cell collection
Quadruplet
← MRD3→
Intensification
Inducti on
CD38MoAbR x 1 year
(Otherwise SOC R maintenance)
Q&A
with panel
98
Relapse & Immune Therapies Ajai Chari, MD
Professor of Clinical Medicine Director of Multiple Myeloma Program University of California, San Francisco
99
Currently Available Anti-Myeloma Agents in 2023 Steroids
Conventional Chemo
ImIDs
Proteasome Inhibitors
Prednisone
Melphalan
Thalidomide
Bortezomib
Dexamethasone
Cyclophosphamide
Lenalidomide
Carfilzomib
Doxorubicin
Pomalidomide
Ixazomib
DCEP/D-PACE
naked antibodie s
bispecific s
METRO28
Off label:
Immunologic approaches Daratumumab (anti-CD38)
Elotuzumab (anti-CS1) Talquetamab anti-GPRC5d*CD3 Teclistamab anti-BCMA*CD3 Elranatamab anti-BCMA*CD3
Bendamustine
idecabtagene vicleucel: anti-BCMA CART
venetoclax
Selinexor
Isatuximab (anti-CD38)
Carmustine
CART s
XPO inhibitor
ciltacabtagene autoleucel: anti-BCMA CART
CART- Chimeric Antigen Receptor – T cell
Currently Available Anti-Myeloma Agents in 2023: Triple Class Exposure Steroids
Conventional Chemo
ImIDs
Proteasome Inhibitors
Prednisone
Melphalan
Thalidomide
Bortezomib
Dexamethasone
Cyclophosphamide
Lenalidomide
Carfilzomib
Doxorubicin
Pomalidomide
Ixazomib
DCEP/D-PACE
naked antibodie s
bispecific s
METRO28
Off label:
Immunologic approaches Daratumumab (anti-CD38)
Elotuzumab (anti-CS1) Talquetamab anti-GPRC5d*CD3 Teclistamab anti-BCMA*CD3 Elranatamab anti-BCMA*CD3
Bendamustine
idecabtagene vicleucel: anti-BCMA CART
venetoclax
Selinexor
Isatuximab (anti-CD38)
Carmustine
CART s
XPO inhibitor
ciltacabtagene autoleucel: anti-BCMA CART
CART- Chimeric Antigen Receptor – T cell
Currently Available Anti-Myeloma Agents in 2023: Penta Drug Exposure Steroids
Conventional Chemo
ImIDs
Proteasome Inhibitors
Prednisone
Melphalan
Thalidomide
Bortezomib
Dexamethasone
Cyclophosphamide
Lenalidomide
Carfilzomib
Doxorubicin
Pomalidomide
Ixazomib
DCEP/D-PACE
naked antibodie s
bispecific s
METRO28
Off label:
Immunologic approaches Daratumumab (anti-CD38)
Elotuzumab (anti-CS1) Talquetamab anti-GPRC5d*CD3 Teclistamab anti-BCMA*CD3 Elranatamab anti-BCMA*CD3
Bendamustine
idecabtagene vicleucel: anti-BCMA CART
venetoclax
Selinexor
Isatuximab (anti-CD38)
Carmustine
CART s
XPO inhibitor
ciltacabtagene autoleucel: anti-BCMA CART
CART- Chimeric Antigen Receptor – T cell
Currently Available Anti-Myeloma Agents in 2023: T cell Redirection Immune Therapies Steroids
Conventional Chemo
ImIDs
Proteasome Inhibitors
Prednisone
Melphalan
Thalidomide
Bortezomib
Dexamethasone
Cyclophosphamide
Lenalidomide
Carfilzomib
Doxorubicin
Pomalidomide
Ixazomib
DCEP/D-PACE
naked antibodie s
bispecific s
METRO28
Off label:
Immunologic approaches Daratumumab (anti-CD38)
Elotuzumab (anti-CS1) Talquetamab anti-GPRC5d*CD3 Teclistamab anti-BCMA*CD3 Elranatamab anti-BCMA*CD3
Bendamustine
idecabtagene vicleucel: anti-BCMA CART
venetoclax
Selinexor
Isatuximab (anti-CD38)
Carmustine
CART s
XPO inhibitor
ciltacabtagene autoleucel: anti-BCMA CART
CART- Chimeric Antigen Receptor – T cell
Months
Progression Free Survival (PFS) and Duration of Response (DOR) Delta of Recently Approved Therapies in RRMM 40 35 30 25 20 15 10 5 0
PFS
T cell redirection therapies
34.933.9
For > 4 LOT and IMID/PI/anti CD38 exposed
8.3 4.2
7.8 3.7
Richardson P et al Blood 2014;123(12):1826-32 Siegel DS et al. Blood 2012;120(14): 2817–2825 Lonial S et al. Lancet 2016;387:1551-1560 Chari A et al. N Eng J Med 2019;381:727-738
7.4 3.7
NR 14.2
3.74.4
18.4 NRNR 12.2 11.3 11.3
Touzeau et al EHA 2023 Nooka A et al ASCO 2022;abstract 8007 (oral presentation) Lesohkin et al Nat Med 2023 Anderson L et al. ASCO 2021;abstract 8016 (poster presentation) Usmani S et al ASCO 2022;abstract 8028 (poster presentation)
aThis is not a head-to-head comparison and cross-trial comparisons should not be interfered from these data Data represent two populations, PFS includes all patients, DOR includes responding patients only
Complex Immunnotherapies For Multiple Myeloma
•Bispecifics – BCMA and non BCMA •monotherapy + combinations
•CART – phase 1 dose escalation studies and randomized phase 3 studies •BCMA sequencing •Logistics of administering T cell redirection therapy •CART vs bispecfiics
Monoclonal Antibodies in All Human Diseases Would Not be Possible Without Myeloma Cells – 1984 Nobel Prize!
Gelboin, H et al. Trends in Pharmacological Sciences, 1999. Wikipedia Adenosine
•
‘84 Georges Köhler, César Milstein, Niels Kaj Jerne shared Nobel Prize in Physiology or Medicine
•
’88 Greg Winter humanized mAbs eliminating the reactions that many monoclonal antibodies (mAbs) caused
•
First mAb for MM not approved until 2015 - 31 years later!
•
Currentlly approved antibodies for MM: • Naked antibodies: daratumumab, isatuximab, elotuzumab • Antibody drug conjugates: belantamb mafadotin
What is a Bispecific Antibody?
Updated from Lancman, et al. ASH 2020.
T/NK Cell Engager Targets in Multiple Myeloma
Lancman, et al. ASH
T/NK cell Engaging Antibody Clinical Trials in Multiple Myeloma Agent AMG420 Pavurutamab AMG701 Alnuctamab CC93269 Elrantamab PF06863135 Linvoseltamab RGN5458 Teclistamab JNJ64007957 ABBV-383 CC-92328 Talquetamab JNJ64407564 Forimtamig RG2634 Cevostamab BFCR4350A GBR1342 AMG424
Targets BCMAxCD3 BCMAxCD3 BCMAxCD3 BCMAxCD3 BCMAxCD3 BCMAxCD3 BCMAxCD3 BCMAxCD16 xNK2GD GPRC5dxCD3 GPRC5dxCD3 * 12 mos FCRH5xCD3 * 12 mos CD38xCD3 CD38xCD3
Phase I I/II I I I/II I I I I I I I/II I
Clinical Trial NCT03836053 NCT03287908 NCT03486067 NCT03269136 NCT03761108 NCT03145181 NCT03933735 NCT04975399 NCT03399799 NCT04557150 NCT03275103 NCT03309111 NCT03445663
Status Completed Closed Ongoing Ongoing Ongoing Ongoing Ongoing Ongoing Ongoing Ongoing Ongoing Ongoing Closed
Updated from Lancman, et al. ASH 2020.
BCMAxCD3 Bispecific Antibodies: Efficacy
Bispecific Antibody
Teclistamab
Elranatamab
Linvoseltamab
ABBV-383
Alnuctamab
HPN217
Treatment
Weekly SC
Weekly SC
Weekly IV
IV every 3 weeks
Weekly -> monthly SQ
Every 2 weeks IV
Patients
n= 165
n= 123
n= 252
n= 174
n= 68
n= 62
Median prior lines
5
5
5
5
4
6
Triple-class refractory
78%
97%
81%
80%
63%
76%
ORR at RP2d
63%
61%
64%
58-61%
65%
73%
PFS
11.3 mos
NE @ 12 mos
NR
13.7 or 11.2 mos
NR
NR
DOR
approval 18.4 Accelerated mos NE @12 mos
89% @ 6 mos
NE
NE
NR
• •
Multiple agents in development, all demonstrating remarkable activity Unprecedented competition is good for the market and ultimately for patients! 110
Cytokine Release Syndrome
Alexander Shimabukuro-Vornhage Journal for ImmunoTherapy of Cancer volume 6, Article number: 56 (2018)
111
BCMAxCD3 Bispecific Antibodies: Safety
Bispecific Antibody
Teclistamab (JNJ-64007957)
Elranatamab (PF-06863135)
Median f/u AEs, (All/(Gr 3+); CRS Infections Neutropenia Neuro # Deaths Hypogamma/IVIg
14.1 mos
10.4 mos
72% (0.6%) 76% (45%) 71% (64%) Neurotoxicity 15% (0.1) 68/(41 due to PD) 75%//39%
58% (0%) 67% (35%) 48% (48%) NR/ PN? 21 (/11 due to PD) 75%/40%
112
BCMA Bispecifics: IgG Levels, Grade 3- 5 Infections, and Benefit of IVIg Protective antibody levels (IgG) on BCMA bispecifics go to zero
•
Replacing the good antibodies with IVIg decreases all severe infections by 80% and severe bacterial infections by 90%
Strategies to reduce infections on BCMA bispecifics: • Vaccinate prior to BCMA bispecific esp COVID • IVIG support for BCMA bispecifics essential • Antibiotics prevention for PJP, shingles • ? less frequent schedule, ? lower maintenance doses, ? fixed duration of therapy (can always retreat later if necc) • good hand hygiene
Lancman, et al. ASH 2022: https://doi.org/10.1182/blood-2022-163733: |. Lancman, et al. Blood Cancer Discovery (2023) vol 4 issue 6
Non-BCMA-Targeted Bispecific Antibodies: Efficacy
Bispecific Antibody
Talquetamab (JNJ-64407564) Phase 1/2 MonumenTAL-1 Study GPRC x CD3
Forimtamig (RG6234) Phase 1 GPRC X CD3 (2:1)
Cevostamab (GO39775) Phase 1 FcRH5 X CD3
Treatment
0.4 mg/kg SQ QW
0.8 mg/kg SC Q2W
Either dose
SQ q 2wk *12 mos
IV q3w * 12 mos
Patients
n=143
n=145
n=51
n=57
n=161
Median prior lines
5
5
6
5
6
Triple-class refractory
74%
69%
63%
85%
ORR @RP2D
74%
73%
64% (at 30-7200 ug)
132-198 mg: (56.7%)
PFS
7.5 mos
11.9 mos
NR
DOR
9.3 mos
13 mos
12.7+ mos
63%
(prior CART/bisp 72%/44%)
Accelerated approval • •
Not only competition within BCMA space but also non BCMA alternatives! Also highly active in phase 1 studies
12.5 mos
Non-BCMA-Targeted Bispecific Antibodies: Safety
Bispecific Antibody
AEs, (All/(Gr 3+) CRS Infections Neutropenia Anemia Thrombocytopenia ICANS # Deaths Hypogamma/IVIg Other • • •
Talquetamab (JNJ-64407564) Phase 1/2 MonumenTAL-1 Study GPRC x CD3 79% (2%) 57% (17%) 34% (31%) 11% (1.6%) 0 due to AEs NR/13% Dysgeusia 48% (N/A) Skin 56% (0%) Nail 52% (0%)
72% (0.7%) 50% (12%) 28% (22%) 10% (1.8%) 0 due to AEs NR/10% Dysgeusia 46% (N/A) Skin 67% (0.7%) Nail 43% (0%)
Cevostamab (GO39775) Phase 1 FcRH5 X CD3 +prophy toci/80% (2%) -> 36% (2.3%) /90%(3.6%) 43% (19%) 18% (16%) -> Gr3+ 64% vs 39% 6 (3.7%) Diarrhea 26% (1%)
CRS common, but not severe manageable • ? Role for preventative medication tociluzuamb Perhaps less infections/lower of neutrophils • This makes GPRC5d antibodies more combinable – with dara and also with tec, PFS 19-20 months! Other new target related toxicities with GPRC5d – taste, skin, nails
Do All MM Patients Need to be Treated Continuously? Early Experience from 1 Year Fixed Duration Therapy
Determinants of the use of bispecifics
Safety- monotherapy CRS Off tumor (? On target) – incidence, time dependency (cumulative?), dose relationship Infection especially COVID complications and deaths Dysgeusia Skin/Nail changes Neuropathy Safety in combination with mAbs, IMIDs, PIs, novel agents
Convenience
Inpatient vs outpatient Cost Reimbursement for drug (J code), inpatient hospitalization, toclluzumab (off label for bispecific), IVIg Ability to give in community Need for & number of priming doses Route of administration – SQ > IV Frequency of administration – q mo Fixed duration vs Treatment to progression
Targets and Sequencing within bispecifics and relative to other agents – CARTs etc.
Time to market BCMA > GPRC5d
CAR-T cell therapy: What is it and how does it work? (1/3)
CAR-T, chimeric antigen receptor-T cell
Image taken from NIH: National cancer institute. CAR-T cell therap. Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/chimeric-antigen-receptor-t-cell-therapy
CAR-T cell therapy: What is it and how does it work? (2/3) Structure of CAR domains
CAR, chimeric antigen receptor; scFv, single-chain variable fragment
•
Tumor binding domain
•
costimulatory endodomains
•
CD3 zeta
June C et al. Science. 2018;359:1361–1365
CAR-T cell therapy: What is it and how does it work? (2/3)
CAR, chimeric antigen receptor
Usmani S. Personal image.
CAR-T cells in myeloma: Currently Available
Phase Target scFv Age, (range) # of lines HR cytog, % EMD, % Triple-R, % ORR, % PFS
Approved CAR-T cells Ide-cel Cilta-cel KarMMa1 CARTITUDE-1 (n = 128) (n = 97) 2,3 II Ib/II BCMA BCMA Chimeric Chimeric mouse Llama 61 (33-78) 61 (56-68) 6 6
35 39 84 81 12.2 m
24 13 88 98 34.9 m
*There, are no head-to-head comparisons of these data and naïve comparison should be conducted with caution BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor; EMD, extramedullary disease; HR cytog, high-risk cytogenetics; NA, not available; NR, not reached/not reported; ScFv, single-chain variable fragment; TCR, T-cell receptor; triple-R, triple-class refractory
CAR-T cells in myeloma: Investigational Therapies
Phase Target scFv Age, (range) # of lines HR cytog, % EMD, % Triple-R, % ORR, % PFS
Alternative Academi manufacturin Human Approved CAR-T c g scFv cells Ide-cel ARI0002h4 P-BCMA-101 Cilta-cel CT0536 CT103A7 1 5,6 LUMMICAR KarMMa CARTITUDE-1 PRIME (n = 128) (n = 30) (n = 53) (n= 79) (n = 24) (n = 97) 2,3 II Ib/II I/II I/II I I/II BCMA BCMA BCMA BCMA BCMA BCMA Chimeric Chimeric Chimeric Humanized Human Human mouse Llama mouse 61 (33-78) 61 (56-68) 61 (36-74) 60 (42-74) 62 (33-76) 57 (39-70) 6 6 4 8 NA 5
35 39 84 81 12.2 m
24 13 88 98 34.9 m
33 20 67 100 53%@18 m
NA NA 60 67 NR
NA NA NA 87 NR
*There, are no head-to-head comparisons of these data and naïve comparison should be conducted with caution BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor; EMD, extramedullary disease; HR cytog, high-risk cytogenetics; NA, not available; NR, not reached/not reported; ScFv, single-chain variable fragment; TCR, T-cell receptor; triple-R, triple-class refractory
34 13 17 95 NR
AlloCAR ALLO-715 UNIVERSAL8 (n = 43) I BCMA
Human 64 (46-77) 5 37 21 91 71 NR
GPRC5 D MCARH OriCAR 1099 -01790 (n= 17 ) (n= 13) I I GPRC5D GPRC5D Humanized Human Bi-epitopic 60 (38-76) 64 (58-68) 6 5.5
76 47 94 71 NR
60 40 15 100 NR
Factors to Consider in BCMA Sequencing
BCMA therapy prior to even ciltacel – PFS is markedly reduced… so sequencing considerations include: mechanism of action, duration of prior BCMA therapy, time since prior BCMA therapy to apheresis/infusion • Loss of BCMA genes • BCMA expression (less likely) - ? Soluble > tissue • Immune T cell fitness (PD-1, TIM3, CD38) and disease burden • Availability of non BCMA directed therapeutics eg. GPRC5d, FCRh5 •
Cohen AD, et al. Blood. 2022:2022015526. Cohen AD, et al. Blood Adv. 2019;3:2487-2490; Samur MK, et al. Nat Commun. 2021;12:868; Da Vià MC, et al. Nat Med. 2021;27:616-619. Lohler et al ASH 2002. Cortes-Selva et al ASH 2022
Pomalidomide/CART/Carfilzomib Randomized Phase 3 Studies % Improvement
40%
40%
40%
50%
75%
40%
40%
35
28.6
Median PFS (mos)
Total N No. prior lines
13.3
12.4
11.53
6.9
6.47
11 .2
19.2
N R
15.2 12
7.1
4.4
ICARIA-MM1 Isa-Pd vs Pd
APOLLO2 D-Pd vs Pd
OPTIMISMM3 PVd vs Vd
CARTITUDE-45 KarMMa-34 Axis TitleCiltacel vs Ide-cel vs SOC DPd or DVd
154 vs 153
151 vs 153
281 vs 278
254 vs:132**
3
2
2
3
208 (175 +20) infus vs 183 or 28 1-3 (~33% 1 LOT)
CANDOR6 DKd vs Kd
IKEMA7 IsaKd vs Kd
312 vs 154
179 vs 123
2
2
CART Side Effects
CARTITUDE-4 Cilta-cel vs Standard of Care Grade 3+ AEs: 97% vs 94% infections 27% vs 25% cytopenias 94% vs 86% CRS: 76% (1% grade 3; no grade 4/5) ICANS: 5% (all grade 1/2) movement and neurocognitive TEAE n=1
Bonifant et al. Molecular therapy oncolytics. 2016.
Considerations in Administration of T cell Redirection Therapies • CRS/ICANS recognition – REMS Program for all involved parties • Floor team - Vital sign frequency • Front line provider- recognition and prompt order entry – consider order sets in EMR (see example on next slide)for • Vitals – to avoid delays in recognition of hypotension/hypoxia requiring interventions • Labs – inflammatory markers, coags, cytokines • Therapeutics - toci, dex, anakinra, siltuximab • Timely drug mixing/administration – pharmacy and floor nurse to coordinate • Notification/training of consultants: neurology, neuroradiology, ICU, infectious disease, ER, outpatient oncology
CAR-T vs Bispecifics In Multiple Myeloma •A hypothetical randomized study without bridging chemo •a CART with a median PFS of < 11-12 mos unlikely to beat an off the shelf bispecific especially with explosive bulky disease •Access and Choice Matter – many more patients have been dosed with bispecifics in clinical trials • including age > 80, including more than several hundreds non-BCMA •What if a CART has median PFS > 2 years? •PFS, OS, QOL unsurpassed •very limited data for TCE in CKD, EF< 40%, in elderly & frail patients, hx of CNS disorders •Auto SCT widely available and cost-effective yet only 12% of MM in US receive it at accredited SCT centers- so until CART availability markedly increases and cost decreases, what % MM patients globally will benefit from CART?
CAR-T vs Bispecifics In Multiple Myeloma
BCMA
Rolls Royce Phantom –rare , hard to get
GPRC5d
BCMA
FCRh5 Toyota Corolla – nearly 50 million sold globally
Conclusions: Treatment Selection for Triple Class-Exposed Multiple Myeloma GOC/Pt preferences Previous Rx w/therapies approved for TCR MM
Not yet eligible for commercial products (> 4 LOT& TCE) but esp for high risk genomic/ISS3/extramed/functional)
CAR T-cell or bispecific antibody study
Adequate organ function (CBC, Cr Cl, EF)
Fit & Cytopenia due to MM or bridging for CAR T-cell
CAR T-cell slot available @ academic site Indolent, nonbulky PD Able to tolerate Grade 2+CRS/neurotox
Yes 96h infusional chemo
Salvage Auto SCT/Boost (stem cells remaining)
Rapid Progression Near academic center
CAR T-cell study
CD38/K/Pom/Cy/Seli based triplet
Cilta-Cel Ide-Cel
Avoid anti-BCMA prior to BCMA CART if possible
Bispecific study CELMoD Modakafusp alpha
Monitor PFS2/OS
Teclistamab Elranatamab Talquetamab
-
impact of T cell exhaustion & antigen expression impact of flu cy if early PD
Q&A
with panel
130
Thank you for Joining! A replay of this program will be made available on our website and shared via email with all attendees
We Want to Hear From You! Feedback Survey At the close of the meeting a feedback survey will pop up. Click “continue” to complete the survey. This will also be emailed to you shortly after the workshop. Please take a moment to complete this survey.
Thank you to our Sponsors!
133